The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism.
about
Bone turnover markers in primary hyperparathyroidism.Contemporary Medical Management of Primary Hyperparathyroidism: A Systematic Review.Mechanisms of multimodal sensing by extracellular Ca(2+)-sensing receptors: a domain-based survey of requirements for binding and signallingClinical Use of Cinacalcet in MEN1 HyperparathyroidismMild primary hyperparathyroidism: a literature review.Novel calcium sensing receptor ligands: a patent survey.Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjectsEffects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism.Pharmacokinetics and pharmacodynamics of cinacalcet in patients with hyperparathyroidism after renal transplantation.Cinacalcet treatment of primary hyperparathyroidismCinacalcet to prevent parathyrotoxic crises in hypercalcaemic patients awaiting parathyroidectomy.Primary hyperparathyroidism: an overview.Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severityClinical and biochemical outcomes of cinacalcet treatment of familial hypocalciuric hypercalcemia: a case seriesCalcimimetics and the treatment of primary and secondary hyperparathyroidism.The calcium-sensing receptor in normal physiology and pathophysiology: a review.Cinacalcet HCl: a novel therapeutic for hyperparathyroidism.Declining Rates of Inpatient Parathyroidectomy for Primary Hyperparathyroidism in the US.Rapid decrease of intact parathyroid hormone could be a predictor of better response to cinacalcet in hemodialysis patients.Asymptomatic primary hyperparathyroidism.Calcimimetics as an adjuvant treatment for familial hypophosphatemic ricketsExperience with cinacalcet in primary hyperparathyroidism: results after 1 year of treatment.The role of calcimimetics in the treatment of hyperparathyroidism.Primary hyperparathyroidism and the skeleton.New strategies for the treatment of hyperparathyroidism incorporating calcimimetics.Activation of the calcium sensing receptor stimulates gastrin and gastric acid secretion in healthy participantsClinical utilization of cinacalcet in hypercalcemic conditions.Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects.Diseases of the parathyroid gland in chronic kidney disease.Cinacalcet hydrochloride for the treatment of hyperparathyroidism.Hypercalcemia in the Intensive Care Unit: A Review of Pathophysiology, Diagnosis, and Modern Therapy.An Interesting Case of Life-Threatening Hypercalcemia Secondary to Atypical Parathyroid Adenoma versus Parathyroid Carcinoma.Predicting G protein-coupled receptor downstream signaling by tissue expression.Asymmetric functioning of dimeric metabotropic glutamate receptors disclosed by positive allosteric modulators.Cinacalcet is effective in the treatment of hyperparathyroidism secondary to malignant transformation of autotransplanted parathyroid tissue. A case report.Investigating the molecular mechanism of positive and negative allosteric modulators in the calcium-sensing receptor dimer.Cinacalcet HCl suppresses Cyclin D1 oncogene-derived parathyroid cell proliferation in a murine model for primary hyperparathyroidism.Cinacalcet for hyperparathyroidism in pregnancy and puerperium.The calcimimetic AMG 641 accelerates regression of extraosseous calcification in uremic rats.Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery.
P2860
Q27692682-790C27AC-C806-48D4-94C3-1AB32D21C399Q33580833-6DAE4B7E-5EB9-490C-8049-15A418F4A70CQ33730598-EB8BD41A-5B14-42CE-A280-DE5E0E11D596Q33879558-C1C7B34F-00DD-4FE8-B60C-0425E54881AFQ34127949-3C921CE1-5797-4074-945C-A87B25D5FFBAQ34170892-816904F3-F35D-4BF4-A4D6-2309D6C60EB8Q34385273-667039D4-9145-4FFB-AB77-06DEA44482F8Q34556949-E501593D-64AC-4920-B567-27CE97853AE0Q34589090-90259B8F-9217-443F-BEEB-E4451B0B1625Q34725416-0D0F6B61-0A1D-4F0E-A03A-9ED26D624279Q34964011-79E06E53-D585-410C-89E4-FB81366BC7EBQ35071213-AF013F3D-1D59-4478-9122-CDB72298DB25Q35468992-586DF99B-EB04-4FFB-8F85-715D893C4003Q35779795-510AEEBE-5427-4F1E-AE4A-91976F36A474Q35915930-258246BB-ABD7-4DCF-96EF-AD7162201ABDQ36033289-1587940A-FA49-4186-8FA0-F67C196B4BC7Q36082068-910F29A4-BC3A-4C1B-8DEC-8725EB05C04AQ36105020-3178A14C-F18E-41A3-A205-3E7709066E64Q36620322-FE24E1C8-BF70-48F4-A297-C41B8AE4A9E4Q36658921-182DC720-EFE5-4B15-A8D8-B839CE32E440Q36662050-2B6E907B-8847-4AB2-9F28-43EA95A492C1Q36883330-D6E11642-70FC-4957-9627-A6DC4CDD78CAQ37013105-DDB2BB57-F71F-4D68-8462-4B6704B2DFACQ37048218-7331D3FD-5A4F-42C5-B86C-06E91B614594Q37111857-F01D71B5-6435-4C37-BE3F-2B585A2F0F0AQ37277550-8636F097-917B-4554-85D5-1B0D60AAC9DCQ37848439-FC29DBFC-3FC1-44B5-89F9-F79361229B66Q37858461-AD822C2F-9A67-4B2C-AB68-DBF1FF12BB1EQ37912038-9435B41A-83AD-4CA1-BF5F-874923D05D8BQ38085702-FE71C2FB-7309-4481-A30C-4986920138D1Q38153026-6AB12909-E25E-424F-9559-5CAB3DD0BA86Q38222752-E565D439-49F7-447B-9CA3-49ED58046CA8Q39531516-F2D58324-A4CD-4DE2-A8E9-F3845E16D06DQ40428691-0456183F-28C8-4366-ADD7-B3138131C611Q41086630-7DE94782-5530-4C07-BFAC-1A42C189E4F0Q42150009-D27AC62A-8DF5-4085-BF48-5EC21C27DCE0Q42741021-A30E9489-3DBE-44FC-83C3-34B98CB6D8FEQ43257730-40DAE21A-4FF6-4A9B-BB4B-56A2A007A07CQ46074765-B1FBCFFA-B4F3-4826-BC6F-583F6C5038E1Q46369997-AE92BBFA-A698-4B5D-85CE-DDCEA33E38B3
P2860
The calcimimetic cinacalcet normalizes serum calcium in subjects with primary hyperparathyroidism.
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The calcimimetic cinacalcet no ...... h primary hyperparathyroidism.
@ast
The calcimimetic cinacalcet no ...... h primary hyperparathyroidism.
@en
The calcimimetic cinacalcet no ...... h primary hyperparathyroidism.
@nl
type
label
The calcimimetic cinacalcet no ...... h primary hyperparathyroidism.
@ast
The calcimimetic cinacalcet no ...... h primary hyperparathyroidism.
@en
The calcimimetic cinacalcet no ...... h primary hyperparathyroidism.
@nl
prefLabel
The calcimimetic cinacalcet no ...... h primary hyperparathyroidism.
@ast
The calcimimetic cinacalcet no ...... h primary hyperparathyroidism.
@en
The calcimimetic cinacalcet no ...... h primary hyperparathyroidism.
@nl
P2093
P356
P1476
The calcimimetic cinacalcet no ...... h primary hyperparathyroidism.
@en
P2093
Dolores M Shoback
Laura C McCary
Matthew D Guo
Munro Peacock
Stewart A Turner
P304
P356
10.1210/JC.2002-021597
P407
P577
2003-12-01T00:00:00Z